

New perspectives in human milk banks

Enrico Bertino¹, Claudia Rossi¹, Paola Di Nicola¹, Chiara Peila¹, Elena Maggiora¹, Liliana Vagliano², Alessandra Coscia¹

¹Neonatal Unit, ²Degree in Pediatric Nursing, Department of Public Health and Pediatrics University of Turin, Italy

Proceedings

Proceedings of the 11th International Workshop on Neonatology and Satellite Meetings
Cagliari (Italy) · October 26th-31st, 2015

From the womb to the adult

Guest Editors: Vassilios Fanos (Cagliari, Italy), Michele Mussap (Genoa, Italy), Antonio Del Vecchio (Bari, Italy), Bo Sun (Shanghai, China), Dorret I. Boomsma (Amsterdam, the Netherlands), Gavino Faa (Cagliari, Italy), Antonio Giordano (Philadelphia, USA)

Abstract

Mother's own milk (MOM) is the first choice in preterm infant feeding, and when it is not available or is insufficient, donor human milk (DHM) is recommended. It has been shown that feeding preterm infants with human milk is less related to major morbidities, enhances feeding tolerance and prevents metabolic syndrome in childhood. As The Committee on Nutrition of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) states, specific guidelines for Human Milk Banks (HMB) are needed to guarantee the best possible compromise between microbiological safety and nutritional/biological quality of human milk (HM).

Currently, Holder pasteurization (HoP: pasteurization process at 62.5-63°C for 30 minutes) is recommended by all international guidelines: this method inactivates bacterial and viral pathogens but it also affects some nutritional and biological properties of human milk. New methods to ameliorate the biological quality and safety of DHM are under investigation in the last years. High Pressure Processing (HPP) is a non-thermal process used in food industries: this technology inactivates pathogenic microorganisms by applying hydrostatic high pressure, however further researches are required before applying this technology in milk banking.

Ultraviolet-C irradiation (UV-C) is another non-thermal method capable of reducing vegetative bacteria in human milk and it also seems to preserve higher levels of immunological proteins than HoP.

High-temperature short-time pasteurization (HTST: flash pasteurization, 72°C for 5-15 seconds) currently is available only at industrial level, but it

could represent an alternative to HoP seeming to maintain the protein profile and some of the key active components of DHM.

Further researches are needed to define the optimal treatment of DHM.

Keywords

Human milk, donor human milk, preterm infants feeding, human milk banking, Holder pasteurization, UV-C, HTST.

Corresponding author

Enrico Bertino, Neonatal Unit, Department of Pediatric and Adolescence Science, University of Turin, Italy; email: enrico.bertino@unito.it.

How to cite

Bertino E, Rossi C, Di Nicola P, Peila C, Maggiora E, Vagliano L, Coscia A. New perspectives in human milk banks. *J Pediatr Neonat Individual Med.* 2015;4(2):e040222. doi: 10.7363/040222.

Introduction

Growing evidence support the use of human milk (HM) for term and preterm infants as well as for sick infants in Neonatal Intensive Care Units (NICUs) [1-3]. Mother's own milk (MOM) is the first choice in preterm infant feeding. When mother's milk is not available or is insufficient, donor human milk (DHM) is recommended [1-5]. Some authors who applied Baby-Friendly Hospital Initiatives to NICUs has considered DHM as one of the supportive measures for the establishment of breastfeeding by [6, 7].

Benefits of feeding with donor human milk

Reduction in the incidence of necrotizing enterocolitis (NEC). The main benefit deriving from the use of DHM vs. formula in preterm infant feeding is the reduction of incidence of necrotizing enterocolitis (NEC) as well explained in some meta-analyses [8-10] and also in some observational studies [10-12].

Reduction in the incidence of sepsis and other infections. A systematic review [13] underlined the protective effect of HM against infections in preterm infants. However, the studies included in this review present a wide heterogenicity regarding the definition of the milk utilized and do not allow to

discriminate the effects deriving specifically from the use of DHM. A large prospective study [14] as well, showed that fresh HM or DHM feeding reduced the risk of late onset sepsis in extremely low birth weight or extremely premature infants. These findings have been confirmed only for fresh MOM in a later study [15]. Further studies evaluating specifically the anti-infective effects of DHM are needed.

Reduction in the incidence of bronchopulmonary dysplasia. It has been shown that DHM feeding significantly reduces the incidence of bronchopulmonary dysplasia in neonates born at a gestational age below 30 weeks [5, 15]. This observation shows an antioxidant activity of HM, which is likely to be maintained also after pasteurization.

Enhancement of feeding tolerance. It has been demonstrated that early initiation of enteral feeding with MOM or DHM even within the first hours of life is well tolerated [16]. In the 1980s few experimental studies observed a lower incidence of feeding intolerance and an earlier establishment of full enteral feeding in preterm infants fed with DHM compared to formula [9].

Prevention of hypertension, insulin resistance, and atherogenic lipoprotein profile. Several studies conducted in large cohorts suggest that adolescents born preterm and fed with human milk present lower risk of metabolic syndrome and lower cardiovascular risk [1-2, 17].

Promotion of breastfeeding in NICU: a recent national survey in Italy observed a positive effects of the availability of DHM on breastfeeding rate of very low birth weight (VLBW) infants at discharge [18], confirming the existing data from Australia [19], USA [20], and Spain [21] which already indicate that the presence of a HMB does not decrease the breastfeeding rate of VLBW infants, but instead, it is supportive for breastfeeding promotion.

Human milk banks

The recent commentary of The Committee on Nutrition of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) states that "DHM should be obtained from established Human Milk Banks (HMBs)

that follow specific guidelines for screening, storage, and handling procedures to optimize its composition while ensuring its safety for the recipient” [5].

Milk handling and processing should always follow the principles of Hazard Analysis and Critical Control Points (HACCP) and should represent the best possible compromise between safety and nutritional/biological quality of the product.

Many countries now have their own HMBs guidelines [23-27].

Donor human milk treatment in human milk banks

Milk delivered to the HMBs should be pasteurized to inactivate viral and bacterial agents [5]. The ideal pasteurization process should consist of a phase of rapid heating, followed by a phase in which the temperature is maintained constant, and a final phase of rapid cooling.

Currently, a pasteurization process at 62.5-63°C for 30 minutes (i.e. the Holder pasteurization [HoP]) is recommended by all international guidelines for constitution of HMBs [27] (level of evidence A: at least two good quality coherent studies, where bias or confounding factors are not present). Pasteurized milk is known to retain many beneficial and protective effects of HM. This method allows a good compromise between microbiological safety and nutritional/biological quality of DHM [2, 4-5, 27]. In fact, it destroys pathogens in milk, including *M. tuberculosis*, and *B. cereus*, as well as some viruses (HIV, HTVL 1-2, Cytomegalovirus, Herpes Simplex and Rubella) [25, 33-39]. But it is also well known that HoP affects some of the nutritional and biological properties of human milk. Several studies have been performed to investigate the effects of Holder pasteurization on these properties of HM and a significant variability in the data is reported in the scientific literature. A possible explanation for the different results may be the heterogeneity of the test protocols applied in the studies (e.g. in terms of sample origin, storage conditions or methods of analysis). Another important source of variability is represented by the fact that often HoP of DHM is simulated on small aliquots, rather than being performed following HMB-implemented protocols. Moreover, modern pasteurizers required significantly less time for heating and cooling than older ones, thus changing the kinetics of the thermal

response for many heat-sensible compounds. Additionally, it appears that some biochemical patterns were investigated more extensively than others, while some other milk components were not considered at all.

The available data confirm that the HoP affects several components of HM (such as immunoglobulins, specific enzymatic activities, vitamins, growth factors and cytokines), even if it is rather difficult to quantify the degradation degree [2, 5].

Furthermore, HoP maintains the bactericidal activity of the milk against *E. coli* better than high temperature short term pasteurization (HTST) [53]. Moreover, although HoP decreases IgA concentration, the remaining molecules effectively inhibit bacterial adhesion (enteropathogenic *E. coli*) [54]. Nonetheless, clinical practice demonstrates that many beneficial properties of HM remains even after pasteurization.

The optimal treatment of DHM should aim to maintain microbiological safety while preserving the highest amount and activity of the milk bioactive components. New methods to improve the biological quality and safety of DHM are under investigation.

High Pressure Processing (HPP) has recently received attention as a novel food preservation method. This non thermal process is an emerging food processing method that can be applied to liquid foods to provide microbiologically safe, nutritionally intact and organoleptically high quality products. This technology inactivates pathogenic microorganisms by applying hydrostatic high pressure (usually 400-800 MPa) to food for short-term treatments (less than 5-10 min). However, further researches are required before applying this technology in milk banking [40-41].

Ultraviolet-C irradiation (UV-C), classified as a non thermal method, seems to be capable of reducing vegetative bacteria in HM as required in HMBs guidelines with no loss of bile salt stimulated lipase (BSSL) and alkaline phosphatase (ALP) activity and no change of fatty acids (FA) [42]. This method also seems to preserve significantly higher levels of immunological proteins than HoP, resulting in bacteriostatic properties similar to those of untreated HM [43].

HTST (flash pasteurization, 72°C for 5-15 seconds) is a pasteurization method in use in the food industries and this thermal treatment has been suggested as an alternative to the HoP.

HTST seems to better retain the protein profile and some of the key active components of DHM (bile salt-stimulated lipase, lactoferrin, IgA, IGFs) if compared to HoP [44-57]. However, this method requires technological investment (a thin layer of milk between two heated metallic walls) and currently is available only at industrial level.

A new high-tech method of flash pasteurization for low quantity of HM has been recently patented by our group and is, at present, ongoing validation.

Declaration of interest

The Authors declare that there is no conflict of interest.

References

1. American Academy of Paediatrics. Breastfeeding and use of human milk. *Pediatrics*. 2012;129:e827-41.
2. Italian Association of Human Milk Banks (Associazione Italiana Banche del Latte Umano Donato); Arslanoglu S, Bertino E, Tonetto P, De Nisi G, Ambruzzi AM, Biasini A, Profeti C, Spreghini MR, Moro GE. Guidelines for the establishment and operation of a donor human milk bank. *J Matern Fetal Neonatal Med*. 2010;23(Suppl 2):1-20.
3. Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, Domellöf M, Embleton ND, Fusch C, Genzel-Boroviczeny O, Goulet O, Kalhan SC, Kolacek S, Koletzko B, Lapillonne A, Mihatsch W, Moreno L, Neu J, Poindexter B, Puntis J, Putet G, Rigo J, Riskin A, Salle B, Sauer P, Shamir R, Szajewska H, Thureen P, Turck D, van Goudoever JB, Ziegler EE; ESPGHAN Committee on Nutrition. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. *J Pediatr Gastroenterol Nutr*. 2010;50(1):85-91.
4. Arslanoglu S, Ziegler EE, Moro GE. Donor human milk in preterm infant feeding: evidence and recommendations. *J Perinat Med*. 2010;38:347-51.
5. Arslanoglu S, Corpeleijn W, Moro G, Braegger C, Campoy C, Colomb V, Decsi T, Domellof M, Fewtrell M, Hojsak I, Mihatsch W, Mølgaard C, Shamir R, Turck D, van Goudoever J, ESPGHAN Committee on Nutrition. Donor Human Milk for Preterm Infants: Current Evidence and Research Directions. *J Pediatr Gastroenterol Nutr*. 2013;57(4):535-42.
6. Maastrup R, Bojesen SN, Kronborg H, Hallstrom I. Breastfeeding support in neonatal intensive care: a national survey. *J Hum Lact*. 2012;28:370-9.
7. Nyqvist KH, Kylberg E. Application of the Baby Friendly Hospital Initiative to neonatal care: suggestions by Swedish mothers of very preterm infants. *J Hum Lact*. 2008;24:252-62.
8. McGuire W, Anthony MY. Donor human milk versus formula for preventing necrotizing enterocolitis in preterm infants: systematic review. *Arch Dis Child Fetal Neonatal Ed*. 2003;88:F11-4.
9. Boyd CA, Quigley MA, Brocklehurst P. Donor breast milk versus infant formula for preterm infants: Systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed*. 2007;92:F169-75.
10. Quigley M, McGuire W. Formula versus donor breast milk for feeding preterm or low birth weight infants. *Cochrane Database Syst Rev*. 2014;4:CD002971.
11. Giuliani F, Prandi G, Coscia A, Cresi F, Di Nicola P, Raia M, Sabatino G, Occhi L, Bertino E. Donor human milk versus mother's own milk in preterm VLBWIs: a case control study. *J Biol Regul Homeost Agents*. 2012;26(3):19-24.
12. Herrmann K, Carroll K. An exclusively human milk diet reduces necrotizing enterocolitis. *Breastfeed Med*. 2014;9(4):184-90.
13. De Silva A, Jones PW, Spencer SA. Does human milk reduce infection rates in preterm infants? A systematic review. *Arch Dis Child Fetal Neonatal Ed*. 2004;89:F509-13.
14. Rønnestad A, Abrahamsen TG, Medbø S, Reigstad H, Lossius K, Kaaresen PI, Englund IE, Irgens LM, Markestad T. Late onset septicemia in a Norwegian national cohort of extremely premature infants receiving very early full human milk feeding. *Pediatrics*. 2005;115:269-76.
15. Schanler RJ, Lau C, Hurst NM, Smith EO. Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. *Pediatrics*. 2005;116:400-6.
16. De Nisi G, Berti M, Malossi R, Pederzini F, Pedrotti A, Valente A. Comparison of neonatal intensive care: Trento area versus Vermont Oxford Network. *Ital J Pediatr*. 2009;14:35:5.
17. Bertino E, Arslanoglu S, Martano C, Di Nicola P, Giuliani F, Peila C, Cester E, Pirra A, Coscia A, Moro G. Biological, nutritional and clinical aspects of feeding preterm infants with human milk. *J Biol Regul Homeost Agents*. 2012;26(3):9-13.
18. Arslanoglu S, Moro GE, Bellù R, Turoli D, De Nisi G, Tonetto P, Bertino E. Presence of human milk bank is associated with elevated rate of exclusive breastfeeding in VLBW infants. *J Perinat Med*. 2013;41(2):129-31.
19. Simmer K, Hartmann B. The knowns and unknowns of human milk banking. *Early Hum Dev*. 2009;85:701-4.
20. Montgomery D, Schmutz N, Baer VL, Rogerson R, Wheeler R, Rowley AM, Lamber DK, Christensen RD. Effects of instituting the "BEST Program" (Breast Milk Early Saves Trouble) in a level III NICU. *J Hum Lact*. 2008;24:248-51.
21. Utrera Torres MI, Medina López C, Vázquez Román S, Alonso Díaz C, Cruz-Rojo J, Fernández Cooke E, Pallás Alonso CR. Does opening a milk bank in a neonatal unit change infant feeding practices? A before and after study. *Int Breastfeed J*. 2010;5:4.
22. Arslanoglu S, Ziegler EE, Moro GE. World Association of Perinatal Medicine (WAPM) Working Group on Nutrition. Recommendations for perinatal practice. Donor human milk in preterm infant feeding: evidence and recommendations. *J Perinatal Med*. 2010;38(4):347-51.

23. Arslanoglu S, Bertino E, Tonetto P, De Nisi G, Ambruzzi AM, Biasini A, Profeti C, Spreghini MR, Moro GE. Guidelines for the establishment and operation of a donor human milk bank. *J Matern Fetal Neonatal Med.* 2010;23(Suppl 2):1-20.
24. HMBANA. Guidelines for the establishment and operation of a donor human milk bank. Available at: <https://www.hmbana.org/guidelines>, published: 2011, last access: August 2015.
25. National Institute for Health and Clinical Excellence (NICE). Donor Breast Milk Banks: The Operation of Donor Milk Bank Services. London: National Institute for Health and Clinical Excellence (UK); 2010 Feb. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22319806>, last access: September 5, 2015.
26. Décret n° 2010-805 du 13 juillet 2010 relatif aux missions, à l'autorisation et aux conditions techniques d'organisation et de fonctionnement des lactariums. Available at: <http://sdp.perinat-france.org/ADLF/legislation.php>, last access: August 2015.
27. Strengthening Human Milk Banking: A Global Implementation Framework. Version 1. Seattle, Washington, USA: Bill & Melinda Gates Foundation Grand Challenges initiative, PATH, 2013.
28. Simmer K, Hartmann B. The knowns and unknowns of human milk banking. *Early Hum Dev.* 2009;85:701-4.
29. Décrets, Arrêtés, Circulaires. Textes Généraux, Ministère de la Santé, de la Jeunesse et des Sports. Décision du 3 décembre 2007 définissant les règles de bonnes pratiques prévues à l'alinéa 3 de l'article L. 3223-1 du code de la santé publique. *Journal Officiel de la République Française*, 5 janvier 2008; texte 22 sur 165.
30. Hartmann BT, Pang WW, Keil AD, Hartmann PE, Simmer K. Best practice guidelines for the operation of a donor human milk bank in an Australian NICU. *Early Hum Dev.* 2007;83:667-73.
31. Arnold LD. Donor milk banking in Scandinavia. *J Hum Lact.* 1999;15:55-9.
32. Omarsdottir S, Casper C, Akerman A, Polberger S, Vanpee M. Breastmilk handling routines for preterm infants in Sweden: a national cross-sectional study. *Breastfeeding Med.* 2008;3:165-70.
33. Ogra PL, Rassin D, Garofalo R. Human milk. In: Remington JS, Klein JO (Eds.). *Infectious diseases of the fetus and newborn infant.* Philadelphia: W.B. Saunders Company, 2006, pp. 211-43.
34. Hamprecht K, Maschmann J, Muller D, Dietz K, Besenthal I, Goelz R, Middeldorp JM, Speer CP, Jahn G. Cytomegalovirus (CMV) inactivation in breastmilk: reassessment of pasteurization and freeze-thawing. *Pediatr Res.* 2004;56:529-35.
35. Maschmann J, Hamprecht K, Weissbrich B, Dietz K, Jahn G, Speer CP. Freeze-thawing of breast milk does not prevent cytomegalovirus transmission to a preterm infant. *Arch Dis Child Fetal Neonatal Ed.* 2006;91:F288-90.
36. Schleiss MR. Role of breast milk in acquisition of cytomegalovirus infection: recent advance. *Curr Opin Pediatr.* 2006;18:48-52.
37. Czank C, Prime DK, Hartmann B, Simmer K, Hartmann PE. Retention of the immunological proteins of pasteurized human milk in relation to pasteurizer design and practice. *Pediatr Res.* 2009;66:374-9.
38. Landers S, Updegrave K. Bacteriological screening of donor human milk before and after Holder pasteurization. *Breastfeed Med.* 2010;5:117-21.
39. Goelz R, Hihn E, Hamprecht K, Dietz K, Jahn G, Poets C, Elmlinger M. Effects of different CMV-heat-inactivation methods on growth factors in human breast milk. *Pediatr Res.* 2009;65:458-61.
40. Sousa SG, Santos MD, Fidalgo LG, Delgadillo I, Saraiva JA. Effect of thermal pasteurisation and high-pressure processing on immunoglobulin content and lysozyme and lactoperoxidase activity in human colostrum. *Food Chem.* 2014;151:79-85.
41. Contador R, Delgado FJ, García-Parra J, Garrido M, Ramírez R. Volatile profile of breast milk subjected to high-pressure processing or thermal treatment. *Food Chemistry.* 2015;180(1):17-24.
42. Christen L, Lai CT, Hartmann PE, Geddes DT. Ultraviolet-C Irradiation: A Novel Pasteurization Method for Donor Human Milk. *PLoS One.* 2013;8(6):e68120.
43. Christen L, Lai CT, Hartmann B, Hartmann PE, Geddes DT. The Effect of UV-C Pasteurization on Bacteriostatic Properties and Immunological Proteins of Donor Human Milk. *PLoS One.* 2013;8(12):e85867.
44. Lawrence RA. Milk banking: the influence of storage procedures and subsequent processing on immunologic components of human milk. *Adv Nutr Res.* 2001;10:389-404.
45. Goes HC, Torres AG, Donangelo CM, Trugo NM. Nutrient composition of banked human milk in Brazil and influence of processing on zinc distribution in milk fractions. *Nutrition.* 2002;18:590-4.
46. Koenig A, de Albuquerque Diniz EM, Barbosa SF, Vaz FA. Immunologic factors in human milk: the effects of gestational age and pasteurization. *J Hum Lact.* 2005;21:439-43.
47. Heiman H, Schanler RJ. Benefits of maternal and donor human milk for premature infants. *Early Hum Dev.* 2006;82:781-7.
48. Conesa C, Rota C, Castillo E, Perez MD, Calvo M, Sanchez L. Antibacterial activity of recombinant human lactoferrin from rice: effect of heat treatment. *Biosci Biotechnol Biochem.* 2009;73:1301-7.
49. Bertino E, Coppa GV, Giuliani F, Coscia A, Gabrielli O, Sabatino G, Sgarrella M, Testa T, Zampini L, Fabris C. Effect of holder pasteurisation on human milk oligosaccharides. *Int J Immunopathol Pharmacol.* 2008;21:381-5.
50. Carratù B, Ambruzzi AM, Fedele E, Sanzini E. Human milk banking: comparison between different pasteurisation temperatures on levels of protein sulfur amino acids. *Amino acids.* 2003;25:150.
51. Carratù B, Ambruzzi AM, Fedele E, Sanzini E. Human milk banking: influence of different pasteurization temperatures on

- levels of protein sulfur amino acids and some free amino acids. *J Food Sci.* 2004;70:C373-5.
52. Wight NE. Donor human milk for preterm infants. *J Perinatol.* 2001;21:249-54.
53. Silvestre D, Ruiz P, Martinez-Costa C, Plaza A, Lopez MC. Effect of pasteurization on the bactericidal capacity of human milk. *J Hum Lact.* 2008;24:371-6.
54. Carbonare SB, Palmeira P, Silva ML, Carneiro-Sampaio MM. Effect of microwave radiation, pasteurization and lyophilization on the ability of human milk to inhibit *Escherichia coli* adherence to HEp-2 cells. *J Diarrhoeal Dis Res.* 1996;14:90-4.
55. Silvestre D, Miranda M, Muriach M, Almansa I, Jareno E, Romero FJ. Antioxidant capacity of human milk: effect of thermal conditions for the pasteurization. *Acta Paediatrica.* 2008;97:1070-4.
56. Baro C, Giribaldi M, Arslanoglu S, Giuffrida MG, Dellavalle G, Conti A, Tonetto P, Biasini A, Coscia A, Fabris C, Moro GE, Cavallarin L, Bertino E. Effect of two pasteurization methods on the protein content of human milk. *Front Biosci (Elite Ed).* 2011;3:818-29.
57. Dhar J, Fichtali J, Skura BJ, Nakai S, Davidson AGF. Pasteurization efficiency of a HTST system for human milk. *J Food Sci.* 1996;61:569-73.